Genomines

Genomines, based in France, is a company dedicated to leveraging synthetic biology for the bioextraction of nickel from contaminated environments. Their innovative processes contribute to sustainable metal sourcing and environmental remediation efforts. Established in Paris, France, in 2021, Genomines focuses on enhancing natural biology through synthetic biology to facilitate the extraction of nickel from contaminated soils. Genomines specializes in utilizing synthetic biology to enhance plants' natural biology for the sustainable extraction of nickel from contaminated soils, including mine tailings and fields with excessive heavy metals.

The company’s core product offering revolves around bioextraction techniques, which improve the ability of plants to absorb nickel efficiently and economically while simultaneously remediating land. This process, often referred to as "phytomining," aims to address the growing demand for nickel, projected to increase significantly due to the energy transition and the need for critical metals in battery production. Genomines serves a diverse client base, including industries focused on sustainable metals, environmental remediation, and sectors engaged in renewable energy technologies, primarily targeting markets in Europe and North America. Genomines generates revenue through strategic partnerships and collaborations with industries requiring sustainable nickel.

Transactions typically occur through B2B arrangements, where clients engage the company for its bioextraction services as part of broader sustainability initiatives. The revenue model may include project-based fees for specific extraction and remediation projects, providing clients with an innovative, cost-effective solution to their metal sourcing needs. While specific pricing plans for individual services are not disclosed, the company’s flagship technologies are positioned to attract interest from sectors focused on reducing their environmental footprint while securing essential raw materials. In August 2025, Genomines raised USD 37 million in series A funding co-led by Engine Ventures and Forbion, with participation from DeepTech and Climate Fund, Hyundai Motor Group’s ZET, Teampact Ventures, Raise Sherpas, Wind, Prospect Innovation, AlphaTech Investment Group, Lowercarbon Capital, First Entrepreneurs Fund, Elemental Impact, and Salida B.

V. also participated in the round. The round was part of a larger USD 45 million equity and debt funding. This funding will support their efforts to enhance existing products and introduce new solutions aimed at improving bioextraction efficiency.

The company is also planning to expand its operations into new geographic markets, particularly targeting regions in North America and Asia by 2026.